GLP-1 Drugs May Reduce Vision Loss and Headache Risk in Intracranial Hypertension: Meta-analysis Finds
USA: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer a more effective therapeutic option than conventional management strategies for idiopathic intracranial hypertension (IIH), a new systematic review and meta-analysis published in the Journal of Neurological Sciences has revealed. The study was led by Warda Ahmed and colleagues, highlighting growing interest in metabolic therapies for neuro-ophthalmic disorders.
IIH is a condition characterised by increased intracranial pressure without an identifiable cause, often leading to headaches, papilledema, and potential vision impairment. Traditional management focuses on weight reduction, diuretics, and, in severe cases, surgical intervention. However, emerging evidence suggests that GLP-1 RAs—originally developed for diabetes and obesity—may provide additional neuroprotective benefits.
The researchers systematically reviewed available literature from MEDLINE and Cochrane databases up to August 2025. Out of 35 initially identified studies, nine met the inclusion criteria, encompassing a total of 13,257 participants. Only studies comparing GLP-1 RA therapy with standard conventional management in adults with IIH were included, while those involving prior treatment exposure were excluded to maintain clarity in outcomes.
Key Findings:
- GLP-1 receptor agonists were associated with significant clinical benefits compared with conventional therapy in idiopathic intracranial hypertension (IIH).
- Patients receiving GLP-1 RAs showed a lower risk of headache, papilledema, and visual deterioration.
- The treatment was also linked to a reduced likelihood of disease progression requiring surgical intervention.
- A reduction in overall mortality risk was observed among patients receiving GLP-1 receptor agonists.
- Quantitatively, GLP-1 RA therapy was associated with a 27% reduction in headache risk.
- A 62% reduction in papilledema risk was reported with GLP-1 RA use.
- Nearly a 49% reduction in the risk of visual worsening was observed.
- The risk of refractory disease requiring surgical management was also lower with GLP-1 RAs.
- Safety analysis showed no significant increase in adverse events compared with conventional treatments.
- The therapeutic benefits may extend beyond weight loss, potentially involving modulation of intracranial pressure, inflammatory pathways, and metabolic dysfunction related to IIH.
Despite encouraging results, the authors emphasize that the evidence base remains limited. The included studies were heterogeneous in design, and most were observational in nature. As a result, the findings should be interpreted cautiously, and the authors call for large-scale randomized controlled trials to confirm efficacy and establish long-term safety.
The study concludes that GLP-1 receptor agonists may represent a promising therapeutic avenue for IIH, particularly in reducing symptom burden and preventing disease progression. However, further high-quality evidence is essential before these agents can be fully integrated into routine clinical practice for this indication.
Reference:
Ahmed W, Gandhi OH, Yu N, Brant J, Hwa T, Bagley L, Tamhankar M, Feroze A, Choudhri O. Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis. J Neurol Sci. 2026 Jan 15;480:125711. doi: 10.1016/j.jns.2025.125711. Epub 2025 Dec 26. PMID: 41468715.
Next Story